NL-OMON39682已完成不适用
A PHASE 1 STUDY OF CC-486 AS A SINGLE AGENT AND IN COMBINATION WITH CARBOPLATIN OR ABI-007 IN SUBJECTS WITH RELAPSED OR REFRACTORY SOLID TUMORS - AZA-ST-001
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Men and women, 18 years or older
- •2. Understand and voluntarily sign an ICD prior to any study-related assessments or procedures are conducted
- •3. Able to adhere to the study visit schedule and other protocol requirements
- •4. Histological or cytological confirmation of relapsed or refractory advanced unresectable solid tumors as listed below for each Arm, including those who have progressed on (or not been able to tolerate) standard anti-cancer therapy
- •* Arm A: CC-486 plus CBDCA:
- •- Urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra (mixed histologies are permitted provided a component of urothelial carcinoma is present)
- •- Epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
- •* Arm B: CC-486 plus ABI-007:
- •- Pancreatic carcinoma
- •* Arm C: CC-486 as a single agent:
- •- Virally associated tumors (tumor types known to be driven by Epstein-Barr virus,
- •Human Papilloma Virus (HPV) and Merkel cell carcinoma of the skin (MC
- •polomavirus):
- •- Nasopharyngeal carcinoma (a minimum of 5 subjects)
- •- cervical carcinoma
- •- Anal carcinoma
- •- Merkel cell carcinioma (MCc)
- •Note: hepatitis B virus (HBV) and hepatitis C virus (HCV) -associated tumors
- •(hepatocellular cancers) are not eligible.
- •Note: head and neck squamous cell cancers (HNSCC) must have HPV-positive
- •status documented to be eligible.
- •5. Consent to screening tumor biopsy (prior to the first dose of CC-486) and at cycle 1 day 15
- •6. Eastern Cooperative Oncology Group (ECOG) Performance Status of * 2.
- •7. Absolute neutrophil count (ANC) * 1.5 x 109/L;
- •Hemoglobin (Hgb) * 90 g/L;
- •Platelets (plt) * 100 x 109/L;
- •Potassium within normal range, or correctable with supplements;
- •AST and ALT * 2.5 x Upper Limit of Normal (ULN) or * 5.0 x ULN if liver tumor is present;
- •Serum total bilirubin * 1.5 x ULN;
- •Serum creatinine * 1.5 x ULN, or 24-hr clearance * 60 mL/min; and,
- •Negative serum pregnancy test within 72 hours before starting study treatment in females of
- •childbearing potential (FCBP).
- •8. Females of child-bearing potential (defined as a sexually mature woman who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or, 2) has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).must:
- •* Agree to the use of a physician-approved contraceptive method (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on CC-486; and for 3 months following the last dose of study medication; and
- •* Have a medically supervised serum pregnancy test with sensitivity of at least 25mIU/mL is to be obtained in FCBP at Screening. A serum pregnancy test should be done within 72 hours prior to Day 1 of starting study therapy (note that the screening serum pregnancy test can be used as the test prior to Day 1 study therapy if it is performed within the 72-hour timeframe). A serum pregnancy test should be done within 72 hours prior to Day 1 of every cycle, and at the Treatment Discontinuation visit. The subject may not receive investigational product until the investigator has verified that the result of the pregnancy test is negative.
- •9. Male subjects with a fe
排除标准
- •1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- •2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
- •3. Any condition that confounds the ability to interpret data from the study.
- •4. Symptomatic central nervous system metastases. Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.
- •5. Known acute or chronic pancreatitis.
- •6. Any peripheral neuropathy * NCI CTCAE grade 2.
- •7. Persistent diarrhea or malabsorption * NCI CTCAE grade 2, despite medical management.
- •8. Impaired ability to swallow oral medication.
- •9. Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart failure.
- •10. Prior systemic cancer-directed treatments or investigational modalities * 5 half lives or 4 weeks, whichever is shorter, prior to starting study drug or who have not recovered from side effects of such therapy.(except alopecia).
- •11. Major surgery * 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- •12. Pregnant or breast feeding.
- •13. Known HIV infection.
- •14. Known chronic hepatitis B or C virus (HBV/HCV) infection, unless this is a comorbidity in subjects with HCC.
- •15. Liver metastases with serum albumin lower or equal to 3 g/dL.
- •16. Other prior cancers within previous 5 years except adequately treated in situ carcinoma cervix, basal or squamous carcinoma of the skin.
- •17. Subjects with >4 prior systemic chemotherapy regimens will require approval by the Celgene medical monitor prior to enrollment.
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors.Advanced HER2-Expressing Solid TumorsMedDRA version: 23.0Level: PTClassification code 10075638Term: HER2 protein overexpressionSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-006812-10-ITBolt Biotherapeutics, Inc.655
未知
1 期
Phase I Study of GDC-0068 as a Single Agent and in Combination with Other Anticancer Drugs in Patients with Advanced Solid Tumors.JPRN-jRCT2080222858CHUGAI PHARMACEUTICAL CO., LTD30
招募中
1 期
A PHASE I STUDY OF ERY974 IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORSJPRN-jRCT2080224729Chugai Pharmaceutical Co., Ltd.39
进行中（未招募）
1 期
A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancersPIK3CA-mutated solid cancers including previously treated recurrent or metastatic HNSCCCancerISRCTN11595117F. Hoffmann-La Roche Ltd40
未知
1 期
PHASE I STUDY OF GDC-0919 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER DRUGS IN PATIENTS WITH ADVANCED SOLID TUMORSJPRN-jRCT2080223275CHUGAI PHARMACEUTICAL CO., LTD.42